Neumora Therapeutics, Inc. Common Stock (NMRA)

What Moves the Stock

1. 01Phase 2 clinical trial data readouts for lead MDD and schizophrenia programs - primary efficacy endpoints and safety profiles drive 30-50% single-day moves typical for CNS biotechs
2. 02FDA regulatory interactions including IND clearances for new programs, Phase 2/3 meeting outcomes, and breakthrough therapy designations
3. 03Strategic partnership announcements or licensing deals that validate platform and provide non-dilutive funding
4. 04Equity financing events and cash runway updates - dilution concerns given negative FCF of $200M annually
5. 05Competitive clinical data from rivals developing novel MOA antidepressants or antipsychotics (e.g., SAGE, RELMADA, AXSM)
6. 06Peer M&A activity in CNS space that establishes valuation benchmarks or suggests takeout potential
7. 07No current revenue - pre-commercial stage with pipeline in Phase 1/2 clinical trials
8. 08Future revenue potential from product sales post-approval (estimated 2027-2029 timeframe for first potential launch)

NMRA Chart

My Notes

• High-risk growth and momentum investors seeking asymmetric returns from binary clinical catalysts.
• High sensitivity to interest rate changes through multiple channels: (1) Valuation impact - biotech DCF models heavily weight distant cash…
• Watch on earnings: Phase 2 trial interim analysis timing and data quality for lead MDD program, Patient enrollment velocity across active clinical trials - delays signal execution risk, Quarterly cash burn rate and ending cash balance - track runway to next financing.